Source: Frontiers in Psychiatry. Unidade: FMRP
Subjects: FÁRMACOS PSICOTRÓPICOS, ALUCINOGÊNICOS, NEUROTRANSMISSORES, SEROTONINA
ABNT
CHAVES, Cristiano et al. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics. Frontiers in Psychiatry, v. 15, p. 1-8, 2024Tradução . . Disponível em: https://doi.org/10.3389/fpsyt.2024.1485337. Acesso em: 26 jan. 2026.APA
Chaves, C., Santos, R. G. dos, Dursun, S. M., Tusconi, M., Carta, M. G., Brietzke, E., & Hallak, J. E. C. (2024). Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics. Frontiers in Psychiatry, 15, 1-8. doi:10.3389/fpsyt.2024.1485337NLM
Chaves C, Santos RG dos, Dursun SM, Tusconi M, Carta MG, Brietzke E, Hallak JEC. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics [Internet]. Frontiers in Psychiatry. 2024 ; 15 1-8.[citado 2026 jan. 26 ] Available from: https://doi.org/10.3389/fpsyt.2024.1485337Vancouver
Chaves C, Santos RG dos, Dursun SM, Tusconi M, Carta MG, Brietzke E, Hallak JEC. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics [Internet]. Frontiers in Psychiatry. 2024 ; 15 1-8.[citado 2026 jan. 26 ] Available from: https://doi.org/10.3389/fpsyt.2024.1485337
